CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Hemocentro de Ribeirão Preto (Institutional affiliation from the last research proposal) Birthplace: Brazil
Coordinator of the Gene Transfer Laboratory of the Ribeirão Preto Blood Center (FMRP/USP). He holds a Bachelor's degree (2010) in Biological Sciences from the School of Philosophy, Sciences and Letters of Ribeirão Preto (USP). He holds a Master's degree in Biomedical Research (2012) and a PhD in Stem Cells and Cell Therapy (2016) from the School of Medicine of Ribeirão Preto (USP). He completed his postdoctoral studies at thematic unit 935 of INSERM (France), focusing on the biology of leukemic stem cells (2019). He is currently developing basic and applied studies in advanced cell therapy, focusing on the development of genetically modified T cells for the treatment of neoplasms. He has regulatory experience in the area of #8203;#8203;advanced therapies, as he was the director of preclinical studies that supported the approval of the clinical trial (CARTHEDRALL-01), which aims to investigate anti-CD19 CAR-T cells in the treatment of leukemia and lymphoma. He also coordinates the development of analytical methods for quality control for CAR-T cells based on digital PCR. Currently, research efforts are directed at understanding the intrinsic and extrinsic mechanisms that regulate the antitumor activity of genetically modified T cells and developing methods that facilitate access and increase the efficacy of these therapies. He is a master's and doctoral advisor in the postgraduate program in Clinical Oncology, Stem Cells and Cell Therapy at the Ribeirão Preto School of Medicine (USP). (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Improving the therapeutic efficacy of CAR-T cells depends on the development of tools that allow real-time, highly sensitive monitoring of their infiltration and persistence. Bioluminescence-based imaging using the reporter enzyme firefly luciferase (FLuc) is the most widely used method for this purpose in nonclinical studies of CAR-T cells. However, the maximum wavelength of light emitte…
Adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR) has shown impressive complete remission rates against B-cell malignancies. However, the efficacy of CAR-T cells against solid tumors, which constitute the majority of neoplasms, is still limited. This is because the microenvironment of solid tumors is dense and decorated with immunosuppressive cells and mo…
Therapy based on the adoptive transfer of T cells expressing chimeric antigen receptors (CAR) have been showing good results in safety and efficacy against B cell malignancies. However, efficacy is still limited in solid tumors, mainly due to mechanisms of immunosuppression, hypoxia , nutrient deprivation and low infiltration of immune cells in the tumor microenvironment. Therefore, a com…
Adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) has demonstrated impressive remission rates against B cell malignancies. However, many cancer patients experience refractoriness or disease relapse due to functional exhaustion of CAR-T cells. Therefore, it is desirable that the final cellular product is enriched with naïve T cells (TN), which have a greater c…
Since the approval of the first cell therapy product for the treatment of neoplasms with CAR-T lymphocytes in 2017, impressive clinical results have been achieved. However, even though this type of immunotherapy is increasingly becoming a form of cancer treatment, especially in hematological tumors, there are several limitations to its use. One of the main restrictions for expanding the c…
Despite the remarkable clinical results, the autologous nature of CAR-T cell manufacturing process restricts the access of patients to this therapy. Therefore, one of the next frontiers in the field is to develop an allogeneic, 'off-the-shelf', CAR-T cell therapy. Initial studies have already provided a proof-of-concept of such "universal" therapy by knocking out the T cell receptor (TCR)…
(Only some records are available in English at this moment)
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has revolutionized cancer treatment, achieving remarkable success in B-cell malignancies. However, its efficacy against solid tumors remains limited, largely due to immunosuppressive tumor microenvironments and poor immune cell infiltration. To overcome these barriers, gamma/delta T cells have emerged as a next-…
The use of autologous T cells expressing chimeric antigen receptors (CAR) has revolutionized the therapy of B-cell neoplasms. However, the use of allogeneic CAR-T cells has numerous advantages over this autologous approach, such as the immediate availability of cryopreserved batches for infusion, standardization of the final cell product, time for multiple genetic modifications in cells, …
| 3 / 3 | Ongoing scholarships in Brazil |
| 6 / 6 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 1 / 1 | Completed scholarships abroad |
| 11 / 11 | All Scholarships |
| Associated processes | |